The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...

Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 30.9% ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.

Guardant Health, Inc. ( NASDAQ: GH) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET AmirAli Talasaz - Co-CEO & Director Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman Michael Bell - Chief ...

PALO ALTO, Calif. (AP) — PALO ALTO, Calif. (AP) — Guardant Health Inc. (GH) on Wednesday reported a loss of $99.9 million in its second quarter. The Palo Alto, California-based company said it had a ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

Despite the indication of a potential risk, people who receive abnormal results on blood-based colorectal screening tests commonly do not receive the follow-up colonoscopy.

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...